BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11341362)

  • 1. Reversible binding of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and its distribution into blood cells in various species.
    Zhou S; Paxton JW; Kestell P; Tingle MD
    J Pharm Pharmacol; 2001 Apr; 53(4):463-71. PubMed ID: 11341362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit.
    Kestell P; Paxton JW; Rewcastle GW; Dunlop I; Baguley BC
    Cancer Chemother Pharmacol; 1999; 43(4):323-30. PubMed ID: 10071984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and reactivity of the major metabolite (beta-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans.
    Zhou SF; Paxton JW; Tingle MD; Kestell P; Jameson MB; Thompson PI; Baguley BC
    Xenobiotica; 2001 May; 31(5):277-93. PubMed ID: 11491389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.
    Zhou S; Kestell P; Baguley BC; Paxton JW
    Invest New Drugs; 2002 Aug; 20(3):281-95. PubMed ID: 12201491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro: implications for prediction of metabolic interactions in vivo.
    Zhou SF; Tingle MD; Kestell P; Paxton JW
    Xenobiotica; 2002 Feb; 32(2):87-107. PubMed ID: 11868972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac.
    Zhou S; Paxton JW; Kestell P; Tingle MD; Ching LM
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):319-26. PubMed ID: 11345648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Zhou S; Kestell P; Tingle MD; Paxton JW
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):126-32. PubMed ID: 11862426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-specific binding of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in liver microsomes from various species.
    Zhou S; Kestell P; Paxton JW
    J Pharm Pharmacol; 2002 Jul; 54(7):997-1003. PubMed ID: 12162720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide.
    Zhou S; Kestell P; Tingle MD; Ching LM; Paxton JW
    Cancer Chemother Pharmacol; 2001 Jun; 47(6):541-4. PubMed ID: 11459209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation.
    Zhou S; Kestell P; Paxton JW
    Drug Metab Rev; 2002 Nov; 34(4):751-90. PubMed ID: 12487149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strain differences in the liver microsomal metabolism of the experimental anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in mice.
    Zhou S; Kestell P; Paxton JW
    J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Sep; 776(2):231-6. PubMed ID: 12138005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.
    Zhou S; Kestell P; Baguley BC; Paxton JW
    Biochem Pharmacol; 2003 Jun; 65(11):1853-65. PubMed ID: 12781337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes.
    Zhou S; Chin R; Kestell P; Tingle MD; Paxton JW
    Br J Clin Pharmacol; 2001 Aug; 52(2):129-36. PubMed ID: 11488768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice.
    Zhao L; Kestell P; Ching LM; Baguley BC
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):20-6. PubMed ID: 11855749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Zhao L; Kestell P; Philpott M; Ching LM; Zhuang L; Baguley BC
    Cancer Chemother Pharmacol; 2001 Jun; 47(6):491-7. PubMed ID: 11459201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.
    Zhou S; Kestell P; Baguley BC; Paxton JW
    Biochem Pharmacol; 2003 Jan; 65(1):109-20. PubMed ID: 12473385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid.
    Zhou S; Paxton JW; Tingle MD; Kestell P
    Drug Metab Dispos; 2000 Dec; 28(12):1449-56. PubMed ID: 11095582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of unbound concentration of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in human plasma by ultrafiltration followed by high-performance liquid chromatography with fluorimetric detection.
    Zhou S; Paxton JW; Tingle MD; Kestell P
    J Chromatogr B Biomed Sci Appl; 2001 Jun; 757(2):359-63. PubMed ID: 11417882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uptake of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and activation of NF-kappaB in human tumor cell lines.
    Woon ST; Baguley BC; Palmer BD; Fraser JD; Ching LM
    Oncol Res; 2002; 13(2):95-101. PubMed ID: 12392157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide.
    Kestell P; Zhao L; Baguley BC; Palmer BD; Muller G; Paxton JW; Ching LM
    Cancer Chemother Pharmacol; 2000; 46(2):135-41. PubMed ID: 10972483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.